Vor Biopharma Inc Dossier - Source-backed chat

Vor Biopharma Inc

VORNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.47

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $19.08Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $1.1B

Enterprise Value $640.2M

Shares Outstanding 55.6M diluted

Next Earnings Date25 Mar 2027

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Vor Biopharma (operating as Vor Bio) has successfully executed a complete corporate transformation, pivoting from its legacy oncology cell therapy platform to a late-stage immunology company focused on telitacicept. Telitacicept is a potential best- and first-in-class recombinant fusion protein that dual-inhibits BLyS (BAFF) and APRIL, targeting the fundamental drivers of B-cell mediated autoimmune diseases. By in-licensing the ex-China rights to telitacicept from RemeGen in mid-2025, Vor Bio bypassed early-stage development risks. The drug is already clinically validated and approved in China for multiple indications, including generalized myasthenia gravis (gMG), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and recently in June 2026, Sjögren's disease (SjD) and IgA nephropathy (IgAN). Backed by a strong cash position of $491.5 million as of March 31, 2026, which extends its operational runway into early 2029, Vor Bio is well-positioned to advance its two global Phase 3 registrational trials (UPSTREAM MG and UPSTREAM SjD). The stock represents a highly asymmetric biotech opportunity with a validated late-stage asset, experienced leadership under CEO Jean-Paul Kress, and a robust balance sheet.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets8 analysts · as of 18 Aug 2026

Low · most bearish analyst$27.00

Mean target$39.00

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$27.0015%

The global Phase 3 UPSTREAM MG trial experiences significant enrollment delays or fails to replicate the strong efficacy seen in Chinese cohorts due to differences in background standard of care or patient demographics. Safety concerns or adverse events emerge, limiting the drug's competitive profile against rival therapies (such as Novartis's zigakibart or Vertex's povetacicept). The cash burn rate accelerates, forcing a highly dilutive capital raise at a depressed stock price.

Base CaseCentral scenario

$39.0060%

Matches the consensus mean

Vor Bio successfully advances both global Phase 3 trials on track. The UPSTREAM MG trial reports positive, clinically meaningful topline results in 1H 2027, confirming the robust efficacy previously demonstrated in RemeGen's Chinese clinical trials. The UPSTREAM SjD trial continues steady enrollment of its ~250-patient cohort. The company maintains its cash runway into early 2029, minimizing dilutive financing needs, and the stock moves toward the consensus analyst target as clinical milestones are achieved.

Bull CaseUpside scenario

$50.0025%

The global Phase 3 UPSTREAM MG trial delivers outstanding topline data in 1H 2027, demonstrating superior efficacy (e.g., >4.5 point improvement on the MG-ADL scale) and a best-in-class safety profile. Concurrently, the UPSTREAM SjD trial in primary Sjögren's disease enrolls ahead of schedule, capitalizing on the lack of approved disease-modifying therapies. Rapid clinical execution and strong commercial positioning lead to a premium valuation or acquisition by a major pharmaceutical company seeking a dominant BAFF/APRIL franchise.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Clinically Validated Lead Asset: Telitacicept is already approved in China for SLE, RA, gMG, and SjD, significantly de-risking its biological mechanism and clinical profile.
Strong Financial Position: With $491.5 million in cash and investments as of Q1 2026, the company has a projected runway extending into early 2029, covering key Phase 3 readouts.
High Unmet Need in Sjögren's Disease: Telitacicept is the only BAFF/APRIL inhibitor in Phase 3 development for SjD, a large market with no currently approved disease-modifying systemic therapies.
Proven Leadership: CEO Jean-Paul Kress, M.D., has a strong track record of successful drug development and corporate exits, notably leading MorphoSys through its acquisition by Novartis in 2024.

Key Investment Risks

Clinical Replication Risk: The global Phase 3 trials must replicate the positive results seen in China within Western clinical trial environments and standard-of-care frameworks.
Competitive Landscape: The BAFF/APRIL and B-cell inhibition space is highly competitive, with major players like Vertex (povetacicept) and Novartis (zigakibart, ianalumab) advancing rival programs.
Single-Asset Dependency: Following the 95% workforce reduction and legacy pipeline halt in 2025, Vor Bio's valuation is almost entirely dependent on the clinical and commercial success of telitacicept.

Thesis Invalidation Triggers

Failure of the global Phase 3 UPSTREAM MG trial to meet its primary efficacy endpoints in 1H 2027.
Severe safety signals or unexpected toxicities emerging in the global clinical trials, leading to FDA clinical holds.
Significant clinical trial enrollment delays that push back key data readouts and exhaust the company's cash runway prematurely.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.